nach oben

Erschienen in:

11.03.2019 | Schwerpunkt

Immunität und Entzündung bei Arteriosklerose

verfasst von: D. Wolf, K. Ley, MD

Erschienen in: Herz | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Solide experimentelle und klinische Evidenz zeigt, dass Arteriosklerose eine chronisch-entzündliche Erkrankung ist. Genomweite Assoziationsstudien (GWAS), bildgebende Verfahren, transgene Mausmodelle und klinische Interventionsstudien zeigen, dass sowohl das angeborene als auch das adaptive Immunsystem Arteriosklerose beschleunigen oder verlangsamen können. In diesem Beitrag fassen wir die Pathogenese der Arteriosklerose zusammen und diskutieren besonders die Rolle des adaptiven Immunsystems. Wir beleuchten einige Einschränkungen von Tiermodellen und betonen die Notwendigkeit, Modelle zu entwickeln, deren Ergebnisse besser auf den Menschen übertragen werden können und letztendlich zu Fortschritten in der Prävention und Behandlung der Arteriosklerose führen.

Gallino A, Aboyans V, Diehm C et al (2014) European Society of Cardiology Working Group on peripheral circulation. Non-coronary atherosclerosis. Eur Heart J 35:1112–1119. https://doi.org/10.1093/eurheartj/ehu071 CrossRefPubMed

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340(NEJM199901143400207):115–126CrossRefPubMed

Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874. https://doi.org/10.1038/nature01323 CrossRefPubMed

Kruk ME, Gage AD, Joseph NT et al (2018) Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 392:2203–2212. https://doi.org/10.1016/S0140-6736(18)31668-4 CrossRefPubMedPubMedCentral

Herrington W, Lacey B, Sherliker P et al (2016) Epidemiology of atherosclerosis and the potential to reduce the Global Burden of Atherothrombotic Disease. Circ Res 118:535–546. https://doi.org/10.1161/CIRCRESAHA.115.307611 CrossRefPubMed

Braunwald E (2012) The treatment of acute myocardial infarction: the past, the present, and the future. Eur Heart J Acute Cardiovasc Care 1:9–12. https://doi.org/10.1177/2048872612438026 CrossRefPubMedPubMedCentral

Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118:547–563. https://doi.org/10.1161/CIRCRESAHA.115.306249 CrossRefPubMed

Ross R, Harker L (1976) Hyperlipidemia and atherosclerosis. Science 193:1094–1100CrossRefPubMed

Ishibashi S, Brown MS, Goldstein JL et al (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883–893. https://doi.org/10.1172/JCI116663 CrossRefPubMedPubMedCentral

10.

Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471CrossRefPubMed

11.

NHLBI Exome Sequencing Project, Do R, Stitziel NO, Won HH et al (2015) Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518:102–106. https://doi.org/10.1038/nature13917 CrossRef

12.

McPherson R, Tybjaerg-Hansen A (2016) Genetics of coronary artery disease. Circ Res 118:564–578. https://doi.org/10.1161/CIRCRESAHA.115.306566 CrossRefPubMed

13.

Kobiyama K, Ley K (2018) Atherosclerosis. Circ Res 123:1118–1120. https://doi.org/10.1161/CIRCRESAHA.118.313816 CrossRefPubMedPubMedCentral

14.

Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ (2014) B cells and humoral immunity in atherosclerosis. Circ Res 114:1743–1756. https://doi.org/10.1161/CIRCRESAHA.113.301145 CrossRefPubMedPubMedCentral

15.

Gimbrone MA Jr, García-Cardeña G (2016) Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res 118:620–636. https://doi.org/10.1161/CIRCRESAHA.115.306301 CrossRefPubMedPubMedCentral

16.

Ley K, Miller YI, Hedrick CC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31:1506–1516. https://doi.org/10.1161/ATVBAHA.110.221127 CrossRefPubMedPubMedCentral

17.

van der Valk FM, Bekkering S, Kroon J et al (2016) Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134:611–624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838 CrossRefPubMedPubMedCentral

18.

Curtiss LK, Tobias PS (2009) Emerging role of Toll-like receptors in atherosclerosi. J Lipid Res 50(suppl):S340–S345. https://doi.org/10.1194/jlr.R800056-JLR200 CrossRefPubMedPubMedCentral

19.

Senders ML, Que X, Cho YS et al (2018) PET/MR imaging of malondialdehyde-acetaldehyde epitopes with a human antibody detects clinically relevant atherothrombosis. J Am Coll Cardiol 71:321–335. https://doi.org/10.1016/j.jacc.2017.11.036 CrossRefPubMedPubMedCentral

20.

Nahrendorf M (2018) Myeloid cell contributions to cardiovascular health and disease. Nat Med 24:711–720. https://doi.org/10.1038/s41591-018-0064-0 CrossRefPubMedPubMedCentral

21.

Duewell P, Kono H, Rayner KJ et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357–1361. https://doi.org/10.1038/nature08938 CrossRefPubMedPubMedCentral

22.

Libby P (2017) Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 70:2278–2289. https://doi.org/10.1016/j.jacc.2017.09.028 CrossRefPubMedPubMedCentral

23.

Tall AR, Yvan-Charvet L (2015) Cholesterol, inflammation and innate immunity. Nat Rev Immunol 15:104–116. https://doi.org/10.1038/nri3793 CrossRefPubMedPubMedCentral

24.

Winkels H, Ehinger E, Vassallo M et al (2018) Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNAsequencing and mass cytometry. Circ Res 122:1675–1688. https://doi.org/10.1161/CIRCRESAHA.117.312513 CrossRefPubMedPubMedCentral

25.

Galkina E, Kadl A, Sanders J et al (2006) Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L‑selectin dependent. J Exp Med 203:1273–1282. https://doi.org/10.1084/jem.20052205 CrossRefPubMedPubMedCentral

26.

Finn AV, Nakano M, Narula J et al (2010) Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 30:1282–1292. https://doi.org/10.1161/ATVBAHA.108.179739 CrossRefPubMed

27.

Stone GW, Maehara A, Lansky AJ et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364:226–235. https://doi.org/10.1056/NEJMoa1002358 CrossRefPubMed

28.

Jonasson L, Holm J, Skalli O et al (1986) Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6:131–138CrossRefPubMed

29.

Adler R (2008) Janeway’s immunobiology. Choice 45:1793–1794

30.

Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22. https://doi.org/10.1146/annurev-immunol-100311-102839 CrossRefPubMed

31.

Koltsova EK, Garcia Z, Chodaczek G et al (2012) Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 122:3114–3126. https://doi.org/10.1172/JCI61758 CrossRefPubMedPubMedCentral

32.

Paulsson G, Zhou X, Törnquist E, Hansson GK (2000) Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E‑deficient mice. Arterioscler Thromb Vasc Biol 20:10–17CrossRefPubMed

33.

Lin Z, Qian S, Gong Y et al (2017) Deep sequencing of the T cell receptor β repertoire reveals signature patterns and clonal drift in atherosclerotic plaques and patients. Oncotarget 8:99312–99322. https://doi.org/10.18632/oncotarget.19892 CrossRefPubMedPubMedCentral

34.

Centa M, Prokopec KE, Garimella MG et al (2018) Acute loss of apolipoprotein E triggers an autoimmune response that accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 38:e145–e158. https://doi.org/10.1161/ATVBAHA.118.310802 CrossRefPubMedPubMedCentral

35.

Caligiuri G, Nicoletti A, Zhou X et al (1999) Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145:301–308CrossRefPubMed

36.

Maganto-García E, Tarrio ML, Grabie N et al (2011) Dynamic changes in regulatory T cells are linked to levels of dietinduced hypercholesterolemia. Circulation 124:185–195. https://doi.org/10.1161/CIRCULATIONAHA.110.006411 CrossRefPubMedPubMedCentral

37.

Colantonio LD, Bittner V, Reynolds K et al (2016) Association of serum lipids and coronary heart disease in contemporary observational studies. Circulation 133:256–264. https://doi.org/10.1161/CIRCULATIONAHA.115.011646 CrossRefPubMed

38.

Gero S, Gergely J, Jakab L et al (1959) Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein. Lancet 2:6–7CrossRefPubMed

39.

Ley K (2016) 2015 Russell Ross memorial lecture in vascular biology: protective autoimmunity in atherosclerosis. Arterioscler Thromb Vasc Biol 36:429–438. https://doi.org/10.1161/ATVBAHA.115.306009 CrossRefPubMedPubMedCentral

40.

Stemme S, Faber B, Holm J et al (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92:3893–3897CrossRefPubMedPubMedCentral

41.

Tse K, Gonen A, Sidney J et al (2013) Atheroprotective vaccination with MHC-II restricted peptides from AopB-100. Front Immunol 4:493CrossRefPubMedPubMedCentral

42.

Kimura T, Kobiyama K, Winkels H et al (2018) Regulatory CD4+ T cells recognize MHC-II-restricted peptide epitopes of apolipoprotein B. Circulation 138:1130. https://doi.org/10.1161/circulationaha.117.031420 CrossRefPubMedPubMedCentral

43.

Moon JJ, Chu HH, Pepper M et al (2007) Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27:203–213. https://doi.org/10.1016/j.immuni.2007.07.007 CrossRefPubMedPubMedCentral

44.

Kimura T, Tse K, Sette A, Ley K (2015) Vaccination to modulate atherosclerosis. Autoimmunity 48:152–160CrossRefPubMedPubMedCentral

45.

Wick G, Jakic B, Buszko M et al (2014) The role of heat shock proteins in atherosclerosis. Nat Rev Cardiol 11:516–529. https://doi.org/10.1038/nrcardio.2014.91 CrossRefPubMed

46.

Zhu J, Quyyumi AA, Rott D et al (2001) Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103:1071–1075CrossRefPubMed

47.

George J, Afek A, Gilburd B et al (2001) Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol 38:900–905CrossRefPubMed

48.

Lawson JS, Glenn WK, Tran DD et al (2015) Identification of human papilloma viruses in atheromatous coronary artery disease. Front Cardiovasc Med 2:17. https://doi.org/10.3389/fcvm.2015.00017 CrossRefPubMedPubMedCentral

49.

Rosenfeld ME, Campbell LA (2011) Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 106:858–867. https://doi.org/10.1160/TH11-06-0392 CrossRefPubMed

50.

Pothineni NVK, Subramany S, Kuriakose K et al (2017) Infections, atherosclerosis, and coronary heart disease. Eur Heart J 38:3195–3201. https://doi.org/10.1093/eurheartj/ehx362 CrossRefPubMed

51.

Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G (1988) Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 72:135–141CrossRefPubMed

52.

Cochain C, Vafadarnejad E, Arampatzi P et al (2018) Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res 122:1661–1674. https://doi.org/10.1161/CIRCRESAHA.117.312509 CrossRefPubMed

53.

Cole JE, Park I, Ahern DJ et al (2018) Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. Cardiovasc Res 114:1360–1371. https://doi.org/10.1093/cvr/cvy109 CrossRefPubMedPubMedCentral

54.

Gräbner R, Lötzer K, Döpping S et al (2009) Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J Exp Med 206:233–248. https://doi.org/10.1084/jem.20080752 CrossRefPubMedPubMedCentral

55.

Li J, McArdle S, Gholami A et al (2016) CCR5+T-bet+FoxP3+ effector CD4 T cells drive atherosclerosis. Circ Res 118:1540–1552. https://doi.org/10.1161/CIRCRESAHA.116.308648 CrossRefPubMedPubMedCentral

56.

Galkina E, Harry BL, Ludwig A et al (2007) CXCR6 promotes atherosclerosis by supporting T‑cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 116:1801–1811. https://doi.org/10.1161/CIRCULATIONAHA.106.678474 CrossRefPubMed

57.

Dansky HM, Charlton SA, Harper MM, Smith JD (1997) T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E‑deficient mouse. Proc Natl Acad Sci Usa 94:4642–4646CrossRefPubMedPubMedCentral

58.

Song L, Leung C, Schindler C (2001) Lymphocytes are important in early atherosclerosis. J Clin Invest 108:251–259. https://doi.org/10.1172/JCI11380 CrossRefPubMedPubMedCentral

59.

Emeson EE, Shen ML, Bell CG, Qureshi A (1996) Inhibition of atherosclerosis in CD4 T‑cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 149:675–685PubMedPubMedCentral

60.

Wolf D, Zirlik A, Ley K (2015) Beyond vascular inflammation—recent advances in understanding atherosclerosis. Cell Mol Life Sci 72:3853–3869. https://doi.org/10.1007/s00018-015-1971-6 CrossRefPubMedPubMedCentral

61.

Robertson AK, Hansson GK (2006) T cells in atherogenesis: for better orfor worse? Arterioscler Thromb Vasc Biol 26:2421–2432. https://doi.org/10.1161/01.ATV.0000245830.29764.84 CrossRefPubMed

62.

Butcher MJ, Filipowicz AR, Waseem TC et al (2016) Atherosclerosisdriven Treg plasticity results in formation of a dysfunctional subset of plastic IFNγ+ Th1/Tregs. Circ Res 119:1190–1203. https://doi.org/10.1161/CIRCRESAHA.116.309764 CrossRefPubMedPubMedCentral

63.

Buono C, Binder CJ, Stavrakis G et al (2005) T‑bet deficiency reduces atherosclerosis and alters plaque antigenspecific immune responses. Proc Natl Acad Sci Usa 102:1596–1601. https://doi.org/10.1073/pnas.0409015102 CrossRefPubMedPubMedCentral

64.

Buono C, Come CE, Stavrakis G et al (2003) Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 23:454–460. https://doi.org/10.1161/01.ATV.0000059419.11002.6E CrossRefPubMed

65.

Gupta S, Pablo AM, Jiang XC et al (1997) IFNgamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99:2752–2761. https://doi.org/10.1172/JCI119465 CrossRefPubMedPubMedCentral

66.

Amento EP, Ehsani N, Palmer H, Libby P (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arter Thromb 11:1223–1230CrossRef

67.

Rocha VZ, Folco EJ, Sukhova G et al (2008) Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 103:467–476. https://doi.org/10.1161/CIRCRESAHA.108.177105 CrossRefPubMedPubMedCentral

68.

Ait-Oufella H, Salomon BL, Potteaux S et al (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12:178–180. https://doi.org/10.1038/nm1343 CrossRefPubMed

69.

Klingenberg R, Gerdes N, Badeau RM et al (2013) Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 123:1323–1334. https://doi.org/10.1172/JCI63891 CrossRefPubMedPubMedCentral

70.

Pinderski Oslund LJ, Hedrick CC, Olvera T et al (1999) Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19:2847–2853CrossRefPubMed

71.

Robertson AK, Rudling M, Zhou X et al (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112:1342–1350. https://doi.org/10.1172/JCI18607 CrossRefPubMedPubMedCentral

72.

Foks AC, Lichtman AH, Kuiper J (2015) Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol 35:280–287. https://doi.org/10.1161/ATVBAHA.114.303568 CrossRefPubMed

73.

Dinh TN, Kyaw TS, Kanellakis P et al (2012) Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 126:1256–1266. https://doi.org/10.1161/CIRCULATIONAHA.112.099044 CrossRefPubMed

74.

Kita T, Yamashita T, Sasaki N et al (2014) Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T‑cell response in mice. Cardiovasc Res 102:107–117. https://doi.org/10.1093/cvr/cvu002 CrossRefPubMed

75.

Caligiuri G, Rudling M, Ollivier V et al (2003) Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 9:10–17CrossRefPubMedPubMedCentral

76.

Gagliani N, Magnani CF, Huber S et al (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19:739–746. https://doi.org/10.1038/nm.3179 CrossRefPubMed

77.

Mallat Z, Gojova A, Brun V et al (2003) Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E‑knockout mice. Circulation 108:1232–1237. https://doi.org/10.1161/01.CIR.0000089083.61317.A1 CrossRefPubMed

78.

Shimizu K, Shichiri M, Libby P et al (2004) Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 114:300–308. https://doi.org/10.1172/JCI19855 CrossRefPubMedPubMedCentral

79.

Engelbertsen D, Andersson L, Ljungcrantz I et al (2013) T‑helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol 33:637–644. https://doi.org/10.1161/ATVBAHA.112.300871 CrossRefPubMed

80.

Mallat Z, Taleb S, Ait-Oufella H, Tedgui A (2009) The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 50(suppl):S364–S369. https://doi.org/10.1194/jlr.R800092-JLR200 CrossRefPubMedPubMedCentral

81.

King VL, Szilvassy SJ, Daugherty A (2002) Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor−/− mice. Arterioscler Thromb Vasc Biol 22:456–461CrossRefPubMed

82.

Smith E, Prasad KM, Butcher M et al (2010) Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E‑deficient mice. Circulation 121:1746–1755. https://doi.org/10.1161/CIRCULATIONAHA.109.924886 CrossRefPubMedPubMedCentral

83.

Gao Q, Jiang Y, Ma T et al (2010) A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 185:5820–5827. https://doi.org/10.4049/jimmunol.1000116 CrossRefPubMed

84.

Nordlohne J, Helmke A, Ge S et al (2018) Aggravated atherosclerosis and vascular inflammation with reduced kidney function depend on interleukin-17 receptor A and are normalized by inhibition of interleukin-17A. JACC Basic Transl Sci 3:54–66. https://doi.org/10.1016/j.jacbts.2017.08.005 CrossRefPubMedPubMedCentral

85.

Danzaki K, Matsui Y, Ikesue M et al (2012) Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E‑deficient mice. Arterioscler Thromb Vasc Biol 32:273–280. https://doi.org/10.1161/ATVBAHA.111.229997 CrossRefPubMed

86.

Gisterå A, Robertson AK, Andersson J et al (2013) Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med 5:196ra100. https://doi.org/10.1126/scitranslmed.3006133 CrossRefPubMed

87.

Brauner S, Jiang X, Thorlacius GE et al (2018) Augmented Th17 differentiation in Trim21 deficiency promotes a stable phenotype of atherosclerotic plaques with high collagen content. Cardiovasc Res 114:158–167. https://doi.org/10.1093/cvr/cvx181 CrossRefPubMed

88.

Gaddis DE, Padgett LE, Wu R et al (2018) Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat Commun 9:1095. https://doi.org/10.1038/s41467-018-03493-5 CrossRefPubMedPubMedCentral

89.

Gisterå A, Klement ML, Polyzos KA et al (2018) Low-density lipoprotein-reactive T cells regulate plasma cholesterol levels and development of atherosclerosis in humanized hypercholesterolemic mice. Circulation 138:2513–2526. https://doi.org/10.1161/CIRCULATIONAHA.118.034076 CrossRefPubMedPubMedCentral

90.

Sage AP, Murphy D, Maffia P et al (2014) MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation 130:1363–1373. https://doi.org/10.1161/CIRCULATIONAHA.114.011090 CrossRefPubMedPubMedCentral

91.

Zernecke A (2015) Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol 35:763–770. https://doi.org/10.1161/ATVBAHA.114.303566 CrossRefPubMed

92.

Koltsova EK, Ley K (2011) How dendritic cells shape atherosclerosis. Trends Immunol 32:540–547. https://doi.org/10.1016/j.it.2011.07.001 CrossRefPubMedPubMedCentral

93.

Kyaw T, Winship A, Tay C et al (2013) Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 127:1028–1039. https://doi.org/10.1161/CIRCULATIONAHA.112.001347 CrossRefPubMed

94.

Kolbus D, Ramos OH, Berg KE et al (2010) CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe⁻(/)⁻ mice. bmc Immunol 11:58. https://doi.org/10.1186/1471-2172-11-58 CrossRefPubMedPubMedCentral

95.

Cochain C, Zernecke A (2016) Protective and pathogenic roles of CD8+ T cells in atherosclerosis. Basic Res Cardiol 111:71. https://doi.org/10.1007/s00395-016-0589-7 CrossRefPubMed

96.

Winkels H, Ley K (2018) Natural killer cells at ease: atherosclerosis is not affected by genetic depletion or hyperactivation of natural killer cells. Circ Res 122:6–7. https://doi.org/10.1161/CIRCRESAHA.117.312289 CrossRefPubMedPubMedCentral

97.

Schiller NK, Boisvert WA, Curtiss LK (2002) Inflammation in atherosclerosis: lesion formation in LDL receptor-deficient mice with perforin and Lyst(beige) mutations. Arterioscler Thromb Vasc Biol 22:1341–1346CrossRefPubMed

98.

Whitman SC, Rateri DL, Szilvassy SJ et al (2004) Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 24:1049–1054. https://doi.org/10.1161/01.ATV.0000124923.95545.2c CrossRefPubMed

99.

Selathurai A, Deswaerte V, Kanellakis P et al (2014) Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc Res 102:128–137. https://doi.org/10.1093/cvr/cvu016 CrossRefPubMed

100.

Nour-Eldine W, Joffre J, Zibara K et al (2018) Genetic depletion or hyperresponsiveness of natural killer cells do not affect atherosclerosis development. Circ Res 122:47–57. https://doi.org/10.1161/CIRCRESAHA.117.311743 CrossRefPubMed

101.

Aslanian AM, Chapman HA, Charo IF (2005) Transient role for CD1drestricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 25:628–632. https://doi.org/10.1161/01.ATV.0000153046.59370.13 CrossRefPubMed

102.

Tupin E, Nicoletti A, Elhage R et al (2004) CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 199:417–422. https://doi.org/10.1084/jem.20030997 CrossRefPubMedPubMedCentral

103.

Li Y, Kanellakis P, Hosseini H et al (2016) A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE−/− mice by reducing lesion necrosis and inflammation. Cardiovasc Res 109:305–317. https://doi.org/10.1093/cvr/cvv259 CrossRefPubMed

104.

Shaw MK, Tse KY, Zhao X et al (2017) T‑cells specific for a self-peptide of ApoB-100 exacerbate aortic atheroma in murine atherosclerosis. Front Immunol 8:95. https://doi.org/10.3389/fimmu.2017.00095 CrossRefPubMedPubMedCentral

105.

Zhou X, Robertson AK, Hjerpe C, Hansson GK (2006) Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 26:864–870. https://doi.org/10.1161/01.ATV.0000206122.61591.ff CrossRefPubMed

106.

Hermansson A, Ketelhuth DF, Strodthoff D et al (2010) Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 207:1081–1093. https://doi.org/10.1084/jem.20092243 CrossRefPubMedPubMedCentral

107.

Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic selftolerance and negative control of immune responses. Annu Rev Immunol 22:531–562. https://doi.org/10.1146/annurev.immunol.21.120601.141122 CrossRefPubMed

108.

Mor A, Luboshits G, Planer D et al (2006) Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 27:2530–2537. https://doi.org/10.1093/eurheartj/ehl222 CrossRefPubMed

109.

George J, Schwartzenberg S, Medvedovsky D et al (2012) Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis 222:519–523. https://doi.org/10.1016/j.atherosclerosis.2012.03.016 CrossRefPubMed

110.

Wigren M, Björkbacka H, Andersson L et al (2012) Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol 32:2000–2004. https://doi.org/10.1161/ATVBAHA.112.251579 CrossRefPubMed

111.

Guasti L, Maresca AM, Schembri L et al (2016) Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment. BMC Cardiovasc Disord 16:26. https://doi.org/10.1186/s12872-016-0201-y CrossRefPubMedPubMedCentral

112.

Mailer RKW, Gisterå A, Polyzos KA et al (2017) Hypercholesterolemia induces differentiation of regulatory T cells in the liver. Circ Res 120:1740–1753. https://doi.org/10.1161/CIRCRESAHA.116.310054 CrossRefPubMed

113.

Cheng HY, Gaddis DE, Wu R et al (2016) Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest 126:3236–3246. https://doi.org/10.1172/JCI83136 CrossRefPubMedPubMedCentral

114.

Mailer RKW, Gisterå A, Polyzos KA et al (2017) Hypercholesterolemia enhances T cell receptor signaling and increases the regulatory T cell population. Sci Rep 7:15655. https://doi.org/10.1038/s41598-017-15546-8 CrossRefPubMedPubMedCentral

115.

Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X et al (2013) Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39:949–962. https://doi.org/10.1016/j.immuni.2013.10.016 CrossRefPubMedPubMedCentral

116.

Komatsu N, Okamoto K, Sawa S et al (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:62–68. https://doi.org/10.1038/nm.3432 CrossRefPubMed

117.

Korn T, Reddy J, Gao W et al (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13:423–431. https://doi.org/10.1038/nm1564 CrossRefPubMedPubMedCentral

118.

Jia L, Zhu L, Wang JZ et al (2013) Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. Atherosclerosis 228:346–352. https://doi.org/10.1016/j.atherosclerosis.2013.01.027 CrossRefPubMed

119.

Joly AL, Seitz C, Liu S et al (2018) Alternative splicing of FOXP3 controls regulatory T cell effector functions and is associated with human atherosclerotic plaque stability. Circ Res 122:1385–1394. https://doi.org/10.1161/CIRCRESAHA.117.312340 CrossRefPubMed

120.

Hilgendorf I, Theurl I, Gerhardt LM et al (2014) Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129:1677–1687. https://doi.org/10.1161/CIRCULATIONAHA.113.006381 CrossRefPubMedPubMedCentral

121.

Sage AP, Nus M, Baker LL et al (2015) Regulatory B cell-specific interleukin-10 is dispensable for atherosclerosis development in mice. Arterioscler Thromb Vasc Biol 35:1770–1773. https://doi.org/10.1161/ATVBAHA.115.305568 CrossRefPubMed

122.

Strom AC, Cross AJ, Cole JE et al (2015) B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. Thromb Haemost 114:835–847. https://doi.org/10.1160/TH14-12-1084 CrossRefPubMed

123.

Srikakulapu P, Hu D, Yin C et al (2016) Artery tertiary lymphoid organs control multilayered territorialized atherosclerosis B‑cell responses in aged ApoE−/− mice. Arterioscler Thromb Vasc Biol 36:1174–1185. https://doi.org/10.1161/ATVBAHA.115.306983 CrossRefPubMedPubMedCentral

124.

Nus M, Sage AP, Lu Y et al (2017) Marginal zone B cells control the response of follicular helper T cells to a high-cholesterol diet. Nat Med 23:601–610. https://doi.org/10.1038/nm.4315 CrossRefPubMed

125.

Caligiuri G, Nicoletti A, Poirier B, Hansson GK (2002) Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 109:745–753. https://doi.org/10.1172/JCI7272 CrossRefPubMedPubMedCentral

126.

Major AS, Fazio S, Linton MF (2002) B‑lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 22:1892–1898CrossRefPubMed

127.

Srikakulapu P, McNamara CA (2017) B cells and atherosclerosis. Am J Physiol Heart Circ Physiol 312:H1060–H1067. https://doi.org/10.1152/ajpheart.00859.2016 CrossRefPubMedPubMedCentral

128.

Hosseini H, Li Y, Kanellakis P et al (2015) Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing b1a lymphocytes. Cardiovasc Res 106:443–452CrossRefPubMed

129.

Chou MY, Fogelstrand L, Hartvigsen K et al (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119:1335–1349. https://doi.org/10.1172/JCI36800 CrossRefPubMedPubMedCentral

130.

Binder CJ, Hörkkö S, Dewan A et al (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9:736–743. https://doi.org/10.1038/nm876 CrossRefPubMed

131.

Grasset EK, Duhlin A, Agardh HE et al (2015) Sterile inflammation in the spleen during atherosclerosis provides oxidation-specific epitopes that induce a protective B‑cell response. Proc Natl Acad Sci Usa 112:E2030–E2038. https://doi.org/10.1073/pnas.1421227112 CrossRefPubMedPubMedCentral

132.

Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S (2003) Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107–2112. https://doi.org/10.1161/01.CIR.0000092891.55157.A7 CrossRefPubMed

133.

Tsimikas S, Brilakis ES, Lennon RJ et al (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48:425–433. https://doi.org/10.1194/jlr.M600361-JLR200 CrossRefPubMed

134.

Hulthe J, Bokemark L, Fagerberg B (2001) Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-yearold subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21:101–107CrossRefPubMed

135.

Dotevall A, Hulthe J, Rosengren A et al (2001) Autoantibodies against oxidized low-density lipoprotein and C‑reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci 101:523–531CrossRef

136.

Ravandi A, Boekholdt SM, Mallat Z et al (2011) Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res 52:1829–1836. https://doi.org/10.1194/jlr.M015776 CrossRefPubMedPubMedCentral

137.

Tsimikas S, Miyanohara A, Hartvigsen K et al (2011) Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol 58:1715–1727. https://doi.org/10.1016/j.jacc.2011.07.017 CrossRefPubMedPubMedCentral

138.

Sjögren P, Fredrikson GN, Samnegard A et al (2008) High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 29:2218–2226. https://doi.org/10.1093/eurheartj/ehn336 CrossRefPubMed

139.

Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O (2001) Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 42:1474–1482PubMed

140.

Hörkkö S, Bird DA, Miller E et al (1999) Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103:117–128. https://doi.org/10.1172/JCI4533 CrossRefPubMedPubMedCentral

141.

Lewis MJ, Malik TH, Ehrenstein MR et al (2009) Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 120:417–426. https://doi.org/10.1161/CIRCULATIONAHA.109.868158 CrossRefPubMedPubMedCentral

142.

Cesena FH, Dimayuga PC, Yano J et al (2012) Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE−/− mice. Atherosclerosis 220:59–65. https://doi.org/10.1016/j.atherosclerosis.2011.10.002 CrossRefPubMed

143.

Que X, Hung MY, Yeang C et al (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301–306. https://doi.org/10.1038/s41586-018-0198-8 CrossRefPubMedPubMedCentral

144.

Kyaw T, Tay C, Krishnamurthi S et al (2011) B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 109:830–840. https://doi.org/10.1161/CIRCRESAHA.111.248542 CrossRefPubMed

145.

Rosenfeld SM, Perry HM, Gonen A et al (2015) B‑1b cells secrete atheroprotective IgM and attenuate atherosclerosis. Circ Res 117:e28–e39. https://doi.org/10.1161/CIRCRESAHA.117.306044 CrossRefPubMedPubMedCentral

146.

Ait-Oufella H, Sage AP, Mallat Z, Tedgui A (2014) Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 114:1640–1660. https://doi.org/10.1161/CIRCRESAHA.114.302761 CrossRefPubMed

147.

Tsimikas S, Palinski W, Witztum JL (2001) Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:95–100CrossRefPubMed

148.

Ylä-Herttuala S, Palinski W, Butler SW et al (1994) Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14:32–40CrossRefPubMed

149.

Björkbacka H, Alm R, Persson M et al (2016) Low levels of apolipoprotein B‑100 autoantibodies are associated with increased risk of coronary events. Arterioscler Thromb Vasc Biol 36:765–771. https://doi.org/10.1161/ATVBAHA.115.306938 CrossRefPubMed

150.

Kyaw T, Tay C, Hosseini H et al (2012) Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE 7:e29371. https://doi.org/10.1371/journal.pone.0029371 CrossRefPubMedPubMedCentral

151.

Kyaw T, Tay C, Khan A et al (2010) Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 185:4410–4419. https://doi.org/10.4049/jimmunol.1000033 CrossRefPubMed

152.

Ait-Oufella H, Herbin O, Bouaziz JD et al (2010) B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 207:1579–1587. https://doi.org/10.1084/jem.20100155 CrossRefPubMedPubMedCentral

153.

Sage AP, Nus M, Bagchi Chakraborty J et al (2017) X‑box binding protein-1 dependent plasma cell responses limit the development of atherosclerosis. Circ Res 121:270–281. https://doi.org/10.1161/CIRCRESAHA.117.310884 CrossRefPubMed

154.

Tay C, Liu YH, Kanellakis P et al (2018) Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G. Arterioscler Thromb Vasc Biol 38:e71–e84. https://doi.org/10.1161/ATVBAHA.117.310678 CrossRefPubMed

155.

Schiopu A, Bengtsson J, Söderberg I et al (2004) Recombinant human antibodies against aldehyde-modified apolipoprotein B‑100 peptide sequences inhibit atherosclerosis. Circulation 110:2047–2052. https://doi.org/10.1161/01.CIR.0000143162.56057.B5 CrossRefPubMed

156.

Schiopu A, Frendéus B, Jansson B et al (2007) Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(−/−)/low-density lipoprotein receptor(−/−) mice. J Am Coll Cardiol 50:2313–2318. https://doi.org/10.1016/j.jacc.2007.07.081 CrossRefPubMed

157.

Lehrer-Graiwer J, Singh P, Abdelbaky A et al (2015) FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. Jacc Cardiovasc Imaging 8:493–494. https://doi.org/10.1016/j.jcmg.2014.06.021 CrossRefPubMed

158.

Palinski W, Miller E, Witztum JL (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci Usa 92:821–825CrossRefPubMedPubMedCentral

159.

Freigang S, Hörkkö S, Miller E et al (1998) Immunization of LDL receptor-deficient mice with homologous malondialdehydemodified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 18:1972–1982CrossRefPubMed

160.

Zhu L, He Z, Wu F et al (2014) Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice. Cardiovasc Diabetol 13:151. https://doi.org/10.1186/s12933-014-0151-6 CrossRefPubMedPubMedCentral

161.

Kimura T, Tse K, McArdle S et al (2017) Atheroprotective vaccination with MHCII-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells. Am J Physiol Heart Circ Physiol 312:H781–H790. https://doi.org/10.1152/ajpheart.00798.2016 CrossRefPubMedPubMedCentral

162.

Fredrikson GN, Söderberg I, Lindholm M et al (2003) Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23:879–884. https://doi.org/10.1161/01.ATV.0000067937.93716.DB CrossRefPubMed

163.

Honjo T, Chyu KY, Dimayuga PC et al (2015) ApoB-100-related peptide vaccine protects against angiotensin II-induced aortic aneurysm formation and rupture. J Am Coll Cardiol 65:546–556. https://doi.org/10.1016/j.jacc.2014.11.054 CrossRefPubMed

164.

Wigren M, Kolbus D, Dunér P et al (2011) Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med 269:546–556. https://doi.org/10.1111/j.1365-2796.2010.02311.x CrossRefPubMed

165.

Herbin O, Ait-Oufella H, Yu W et al (2012) Regulatory T‑cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32:605–612. https://doi.org/10.1161/ATVBAHA.111.242800 CrossRefPubMed

166.

Klingenberg R, Lebens M, Hermansson A et al (2010) Intranasal immunization with an apolipoprotein B‑100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 30:946–952. https://doi.org/10.1161/ATVBAHA.109.202671 CrossRefPubMed

167.

Hermansson A, Johansson DK, Ketelhuth DF et al (2011) Immunotherapy with tolerogenic apolipoprotein B‑100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 123:1083–1091. https://doi.org/10.1161/CIRCULATIONAHA.110.973222 CrossRefPubMed

168.

Kobiyama K, Vassallo M, Mitzi J et al (2018) A clinically applicable adjuvant for an atherosclerosis vaccine in mice. Eur J Immunol 48:1580–1587. https://doi.org/10.1002/eji.201847584 CrossRefPubMedPubMedCentral

169.

Gisterå A, Hermansson A, Strodthoff D et al (2017) Vaccination against T‑cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. J Intern Med 281:383–397. https://doi.org/10.1111/joim.12589 CrossRefPubMed

170.

Wigren M, Bengtsson D, Dunér P et al (2009) Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 104:e62–e70. https://doi.org/10.1161/CIRCRESAHA.109.196667 CrossRefPubMed

171.

Khallou-Laschet J, Tupin E, Caligiuri G et al (2006) Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 184:330–341. https://doi.org/10.1016/j.atherosclerosis.2005.04.021 CrossRefPubMed

172.

Buscher K, Ehinger E, Gupta P et al (2017) Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival. Nat Commun 8:16041. https://doi.org/10.1038/ncomms16041 CrossRefPubMedPubMedCentral

173.

Bennett BJ, Davis RC, Civelek M et al (2016) Correction: genetic architecture of atherosclerosis in mice: a systems genetics analysis of common inbred strains. plos Genet 12:e1005913. https://doi.org/10.1371/journal.pgen.1005913 CrossRefPubMedPubMedCentral

174.

Beura LK, Hamilton SE, Bi K et al (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512–516. https://doi.org/10.1038/nature17655 CrossRefPubMedPubMedCentral

175.

Mihaylova B, Emberson J, Blackwell L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590. https://doi.org/10.1016/S0140-6736(12)60367-5 CrossRefPubMed

176.

Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C‑reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646 CrossRefPubMed

177.

Schönbeck U, Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:II18–II26. https://doi.org/10.1161/01.CIR.0000129505.34151.23 CrossRefPubMed

178.

Nicholls SJ, Ballantyne CM, Barter PJ et al (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087. https://doi.org/10.1056/NEJMoa1110874 CrossRefPubMed

179.

Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489–1499. https://doi.org/10.1056/NEJMoa1501031 CrossRefPubMed

180.

Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722. https://doi.org/10.1056/NEJMoa1615664 CrossRefPubMed

181.

Sahebkar A, Di Giosia P, Stamerra CA et al (2016) Effect of monoclonal antibodies to PCSK9 on high-sensitivity C‑reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol 81:1175–1190. https://doi.org/10.1111/bcp.12905 CrossRefPubMedPubMedCentral

182.

Bohula EA, Giugliano RP, Leiter LA et al (2018) Inflammatory and cholesterol risk in the FOURIER Trial. Circulation 138:131–140. https://doi.org/10.1161/CIRCULATIONAHA.118.034032 CrossRefPubMed

183.

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:404–410. https://doi.org/10.1016/j.jacc.2012.10.027 CrossRefPubMed

184.

Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

185.

Ridker PM, Everett BM, Pradhan A et al (2018) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. https://doi.org/10.1056/NEJMoa1809798 CrossRefPubMedPubMedCentral

186.

Taleb A, Tsimikas S (2012) Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold? Expert Rev Cardiovasc Ther 10:399–402. https://doi.org/10.1586/erc.12.32 CrossRefPubMed

Titel: Immunität und Entzündung bei Arteriosklerose
verfasst von: D. Wolf
K. Ley, MD
Publikationsdatum: 11.03.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-4790-y

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Critical inflammatory mechanisms underlying arrhythmias

Krebserkrankungen heilen und das Herz schützen

Herzklappenerkrankungen: Wie aufgeklärt ist die deutsche Bevölkerung?

Vitamin D deficiency and functional response to CRT in heart failure patients